National Wealth Management Group LLC Invests $374,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

National Wealth Management Group LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,358 shares of the specialty pharmaceutical company’s stock, valued at approximately $374,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. California State Teachers Retirement System raised its holdings in Jazz Pharmaceuticals by 3.2% in the first quarter. California State Teachers Retirement System now owns 102,353 shares of the specialty pharmaceutical company’s stock worth $12,325,000 after purchasing an additional 3,172 shares during the period. Tidal Investments LLC lifted its holdings in Jazz Pharmaceuticals by 179.4% during the first quarter. Tidal Investments LLC now owns 16,655 shares of the specialty pharmaceutical company’s stock worth $2,006,000 after acquiring an additional 10,693 shares in the last quarter. Plato Investment Management Ltd bought a new position in Jazz Pharmaceuticals during the first quarter worth about $228,000. Virtu Financial LLC grew its stake in Jazz Pharmaceuticals by 31.8% in the first quarter. Virtu Financial LLC now owns 11,696 shares of the specialty pharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 2,819 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its position in shares of Jazz Pharmaceuticals by 45.3% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 161,388 shares of the specialty pharmaceutical company’s stock worth $19,434,000 after purchasing an additional 50,300 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This represents a 0.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock worth $720,160 over the last ninety days. Insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research reports. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Finally, JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $122.64 on Thursday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a market cap of $7.41 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57. The business’s 50 day moving average price is $114.43 and its two-hundred day moving average price is $110.98. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.